Neuroimaging advances regarding subjective cognitive decline in preclinical Alzheimer's disease.

ABSTRACT: Subjective cognitive decline (SCD) is regarded as the first clinical manifestation in the Alzheimer's disease (AD) continuum. Investigating populations with SCD is important for understanding the early pathological mechanisms of AD and identifying SCD-related biomarkers, which are critical for the early detection of AD. With the advent of advanced neuroimaging techniques, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), accumulating evidence has revealed structural and functional brain alterations related to the symptoms of SCD. In this review, we summarize the main imaging features and key findings regarding SCD related to AD, from local and regional data to connectivity-based imaging measures, with the aim of delineating a multimodal imaging signature of S

SUBMITTER: Wang X 

PROVIDER: S-EPMC7507636 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature